AU2010267775C1 - Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy - Google Patents

Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy Download PDF

Info

Publication number
AU2010267775C1
AU2010267775C1 AU2010267775A AU2010267775A AU2010267775C1 AU 2010267775 C1 AU2010267775 C1 AU 2010267775C1 AU 2010267775 A AU2010267775 A AU 2010267775A AU 2010267775 A AU2010267775 A AU 2010267775A AU 2010267775 C1 AU2010267775 C1 AU 2010267775C1
Authority
AU
Australia
Prior art keywords
thcv
seizures
cbd
seizure
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010267775A
Other languages
English (en)
Other versions
AU2010267775A1 (en
AU2010267775B2 (en
Inventor
Geoffrey Guy
Tetsuro Kikuchi
Gary Stephens
Ben Whalley
Claire Williams
Stephen Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Operations Uk Ltd
Original Assignee
Jazz Pharmaceuticals Operations Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41008705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010267775(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Operations Uk Ltd filed Critical Jazz Pharmaceuticals Operations Uk Ltd
Publication of AU2010267775A1 publication Critical patent/AU2010267775A1/en
Application granted granted Critical
Publication of AU2010267775B2 publication Critical patent/AU2010267775B2/en
Publication of AU2010267775C1 publication Critical patent/AU2010267775C1/en
Assigned to GW PHARMA LTD. reassignment GW PHARMA LTD. Request for Assignment Assignors: GW PHARMA LIMITED, OTSUKA PHARMACEUTICAL CO. LIMITED
Assigned to JAZZ PHARMACEUTICALS OPERATIONS UK LIMITED reassignment JAZZ PHARMACEUTICALS OPERATIONS UK LIMITED Request to Amend Deed and Register Assignors: GW PHARMA LTD.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2010267775A 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy Active AU2010267775C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0911580A GB2471523A (en) 2009-07-03 2009-07-03 Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB0911580.9 2009-07-03
PCT/GB2010/051066 WO2011001169A1 (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy

Publications (3)

Publication Number Publication Date
AU2010267775A1 AU2010267775A1 (en) 2012-02-23
AU2010267775B2 AU2010267775B2 (en) 2016-10-06
AU2010267775C1 true AU2010267775C1 (en) 2020-02-27

Family

ID=41008705

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010267775A Active AU2010267775C1 (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy

Country Status (28)

Country Link
US (4) US9066920B2 (enExample)
EP (3) EP2727626A1 (enExample)
JP (2) JP5904938B2 (enExample)
KR (1) KR101727000B1 (enExample)
CN (2) CN102596322A (enExample)
AR (1) AR077448A1 (enExample)
AU (1) AU2010267775C1 (enExample)
BR (1) BR112012000076A2 (enExample)
CA (2) CA3040410C (enExample)
CY (1) CY1115338T1 (enExample)
DK (1) DK2448637T4 (enExample)
ES (1) ES2460623T5 (enExample)
GB (3) GB2471523A (enExample)
HR (1) HRP20140398T4 (enExample)
IL (1) IL217280B (enExample)
IN (1) IN2012DN00804A (enExample)
MX (1) MX2012000257A (enExample)
MY (1) MY156759A (enExample)
NZ (2) NZ620838A (enExample)
PL (1) PL2448637T5 (enExample)
PT (1) PT2448637E (enExample)
RU (1) RU2563143C2 (enExample)
SG (1) SG176914A1 (enExample)
SI (1) SI2448637T2 (enExample)
TW (1) TWI461191B (enExample)
UA (1) UA108852C2 (enExample)
WO (1) WO2011001169A1 (enExample)
ZA (1) ZA201200373B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
KR20070089151A (ko) 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US11062795B2 (en) 2007-03-02 2021-07-13 Enigami Systems, Inc. Healthcare data system
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2479153B (en) * 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US10319475B1 (en) 2014-06-13 2019-06-11 Enigami Systems, Inc. Method and apparatus for determining relationships between medications and symptoms
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
CA2961410C (en) 2014-09-16 2023-07-11 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
EP3247359A4 (en) 2015-01-25 2018-08-08 India Globalization Capital, Inc. Composition and method for treating seizure disorders
WO2016123475A1 (en) 2015-01-31 2016-08-04 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
WO2016160542A1 (en) * 2015-04-01 2016-10-06 India Globalization Capital, Inc. Composition and method for treating seizure disorders
EP3288592A4 (en) * 2015-04-28 2019-01-09 The Regents of The University of California USE OF CANNABIDIOL FOR THE TREATMENT OF CHILDREN'S SPAS
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
WO2017091764A1 (en) 2015-11-24 2017-06-01 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
EP3471746A4 (en) 2016-06-15 2020-02-26 India Globalization Capital, Inc. METHOD AND COMPOSITION FOR TREATING CRAMPING SEASONS
US10143706B2 (en) 2016-06-29 2018-12-04 Cannscience Innovations, Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
CN108236608B (zh) * 2016-12-27 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与氨己烯酸的药物组合物及其用途
CN108245510B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途
CN108245517B (zh) * 2016-12-29 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与拉莫三嗪的药物组合物及其用途
CN108245499B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与双链脂肪酸类抗癫痫药物的组合物及其用途
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
CN108785298A (zh) * 2017-04-27 2018-11-13 汉义生物科技（北京）有限公司 一种用于治疗癫痫的药物组合物、其制备方法及用途
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB2583526A (en) 2019-05-03 2020-11-04 Gw Res Ltd Use of cannabidiol in the treatment of tuberous sclerosis complex
CN110101804A (zh) * 2019-05-30 2019-08-09 厦门梓素生物科技有限公司 一种含大麻二酚提取物的癫痫药物组合及其制备方法
JP2022547136A (ja) * 2019-09-17 2022-11-10 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 発達性及びてんかん性脳症における行動障害の治療
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
EP3912485A1 (en) 2020-05-18 2021-11-24 Del-Vis Sp. z o.o. Cigarette product and a method for manufacturing the product
WO2022017936A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597279A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
AU2021318553A1 (en) 2020-07-28 2023-03-23 Impello Biosciences Inc. Methods and compositions for altering secondary metabolites in plants
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
GB2604132A (en) 2021-02-25 2022-08-31 Gw Res Ltd Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromes
US11337934B1 (en) 2021-04-08 2022-05-24 Lanny Leo Johnson Compositions including a cannabinoid and protocatechuic acid
CN118510544A (zh) 2021-07-29 2024-08-16 爱莫里大学 大麻素类的磷酸酯前药
JP2025512495A (ja) * 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040049059A1 (en) * 2000-10-17 2004-03-11 Adam Mueller Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts
US20050042172A1 (en) * 2001-10-31 2005-02-24 Whittle Brian Anthony Administration of medicaments by vaporisation
WO2007148094A1 (en) * 2006-06-23 2007-12-27 Gw Pharma Limited Cannabinoids for use in the treatment of neuropathic pain

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
EP2298284A3 (en) * 2001-02-14 2013-12-18 GW Pharma Limited Mucoadhesive pharmaceutical formulations
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
ITPD20020138A1 (it) 2002-05-24 2003-11-24 Matteo Bevilacqua Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
PL215220B1 (pl) * 2002-08-14 2013-11-29 Gw Pharma Ltd Ciekly preparat farmaceutyczny
JP4657716B2 (ja) 2002-08-14 2011-03-23 ジーダブリュー・ファーマ・リミテッド 植物材料からの薬学的に活性な成分の抽出の改良
KR20070089151A (ko) * 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
US9877928B2 (en) 2006-05-30 2018-01-30 Air Systems, Inc. Gear drive damper
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
ES2727648T3 (es) 2008-03-26 2019-10-17 Stichting Sanammad Composiciones de goma de mascar que comprenden cannabinoides
GB2478072B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478074B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2479153B (en) 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
RU2639120C2 (ru) 2011-08-26 2017-12-19 Биал-Портела Энд Ка, С.А. Лечение с использованием ацетата эсликарбазепина или эсликарбазепина
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
US20150181924A1 (en) 2013-10-31 2015-07-02 Michael R. Llamas Cannabidiol liquid composition for smoking
WO2015142501A1 (en) 2014-03-21 2015-09-24 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
MX387604B (es) 2014-05-29 2025-03-18 Insys Pharma Inc Formulaciones cannabinoides estables.
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040049059A1 (en) * 2000-10-17 2004-03-11 Adam Mueller Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts
US20050042172A1 (en) * 2001-10-31 2005-02-24 Whittle Brian Anthony Administration of medicaments by vaporisation
WO2007148094A1 (en) * 2006-06-23 2007-12-27 Gw Pharma Limited Cannabinoids for use in the treatment of neuropathic pain

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
Benowitz & Jones: "Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man," Journal of Clinical Pharmacology, 1981, vol. 21, pp. 214S-223S *
Benowitz et al.: "Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction," Clinical Pharmacology & Therapeutics, 1980, vol. 28, no. 1, pp. 115-120 *
Bhattacharyya et al.: "Modulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol," Archives of General Psychiatry, April 2009, vol. 66, no. 4, pp. 442-451 *
Braida et al.: "Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils", Neuroscience Letters, 2003, vol. 346, pp. 61-64 *
Carlini et al.: "Hypnotic and Antiepileptic Effects of Cannabidiol", Journal of Clinical Pharmacology, 1981, vol. 21, Issue S1,: pp. 417S-427S *
Chiu et al.: "The influence of cannabidiol and Δ9-tetrahydrocannabinol on cobalt epilepsy in rats", Epilepsia, 1979, vol. 20, pp. 365-375 *
Commision on Classification and Terminology of the International League Against Epilepsy: "Proposal for revised clinical and electroencephalographic classification of epileptic seizures," Epilepsia, 1981, vol. 22, pp. 489-501 *
Consroe et al.: "Controlled clinical trial of cannabidiol in Huntington’s Disease," Pharmacology Biochemistry & Behavior, 1991, vol. 40, pp. 701-708 *
Consroe et al.: "Open label evaluation of cannabidiol in dystonic movement disorders," International Journal of Neuroscience, 1986, vol. 30, pp. 277-282 *
Cunha et al.: "Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients", Pharmacology, 1980, vol. 21, pp. 175-185 *
Engel: "Report of the ILAE Classification Core Group," Epilepsia, 2006, vol. 47, no. 9, pp 1558-1568 *
Gaoni & Mechoulam: "The isolation and structure of Δ1-tetrahydrocannabinol and other neutral cannabinoids from hashish", Journal of the American Chemical Society, 1971, vol. 93, no. 1, pp. 217-224 *
Guimaraes et al.: "Antianxiety effect of cannabidiol in the elevated plusmaze," Psychopharmacology,1990, vol. 100, pp. 558-59 *
Karler & Turkanis: "The cannabinoids as potential antiepileptics", Journal of Clinical Pharmacology, 1981, vol. 21, pp. 437S-448S *
Karler et al.: "The anticonvulsant activity of cannabidiol and cannabinol," Life Sciences, 1973, vol. 13, pp. 1527-1531 *
Lindamood & Colasanti: "Effects of Δ9-tetrahydrocannabinol and cannabidiol on sodium-dependent high affinity choline uptake in the rat hippocampus," Journal of Pharmacology & Experimental Therapeutics, 1980, vol. 213, no. 2, pp. 216-221 *
Malfait et al.: "The non-psychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis," Proceedings of the National Academy of Sciences, 2000, vol. 97, no. 17, pp. 9561-9566 *
McNamara, J.O., "Pharmacotherapy of the epilepsies," Chapter 19 in Goodman & Gilman’s Pharmacological Basis for Therapeutics, Eleventh Edition, Brunton, L.L. et al., eds., McGraw Hill Cos., Inc., New York (2006), pp. 501-525 *
Mechoulam et al.: "Cannabidiol: An overview of some pharmacological aspects," Journal of Clinical Pharmacology, 2002, vol. 42, pp. 11S-19S *
Pertwee: "The Pharmacology and Therapeutic Potential of Cannabidiol," in Cannabinoids, V, Di Marzo, ed., Landes Bioscience, Georgetown, Texas, USA (2004) pp. 32-83 *
Sandyk et al.: "Preliminary trial of cannabidiol in Huntington’s Disease," in Marihuana: An International Research Report, G. Chesher et al., eds. Australian Gov. Publ. Service, Canberra NSW (1988), pp. 157-162 *
U.S. Department of Health and Human Services FDA for Drug Evaluation and Research (CDER): "Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers" (2005)) *
Wallace et al.: "Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects," European Journal of Pharmacology, 2001, vol. 428, pp. 51-57 *

Also Published As

Publication number Publication date
AR077448A1 (es) 2011-08-31
CA3040410A1 (en) 2011-01-06
CN106236744A (zh) 2016-12-21
GB2471565B (en) 2012-07-04
GB2471565A (en) 2011-01-05
CA2766082A1 (en) 2011-01-06
DK2448637T4 (da) 2022-09-12
GB2485291B (en) 2013-03-27
ZA201200373B (en) 2012-09-26
GB2471523A (en) 2011-01-05
HRP20140398T1 (hr) 2014-06-20
MX2012000257A (es) 2012-01-27
PL2448637T5 (pl) 2022-10-03
SI2448637T2 (sl) 2022-10-28
EP2448637B2 (en) 2022-06-08
GB2485291A (en) 2012-05-09
JP5904938B2 (ja) 2016-04-20
CA3040410C (en) 2023-03-28
IL217280B (en) 2018-05-31
TWI461191B (zh) 2014-11-21
US20190247324A1 (en) 2019-08-15
SG176914A1 (en) 2012-01-30
KR20120088648A (ko) 2012-08-08
ES2460623T5 (es) 2022-10-14
AU2010267775A1 (en) 2012-02-23
HRP20140398T4 (hr) 2022-10-14
US20170273913A1 (en) 2017-09-28
EP2448637B1 (en) 2014-03-12
JP2012532093A (ja) 2012-12-13
BR112012000076A2 (pt) 2020-06-02
IN2012DN00804A (enExample) 2015-06-26
US20120165402A1 (en) 2012-06-28
US9522123B2 (en) 2016-12-20
US20150335590A1 (en) 2015-11-26
EP2727626A1 (en) 2014-05-07
DK2448637T3 (da) 2014-05-26
EP3718603A1 (en) 2020-10-07
GB201121919D0 (en) 2012-02-01
EP2448637A1 (en) 2012-05-09
CY1115338T1 (el) 2017-01-04
WO2011001169A1 (en) 2011-01-06
CN102596322A (zh) 2012-07-18
US9066920B2 (en) 2015-06-30
AU2010267775B2 (en) 2016-10-06
RU2563143C2 (ru) 2015-09-20
IL217280A0 (en) 2012-02-29
HK1164766A1 (en) 2012-09-28
GB0911580D0 (en) 2009-08-12
KR101727000B1 (ko) 2017-05-02
GB201010897D0 (en) 2010-08-11
NZ620838A (en) 2015-08-28
SI2448637T1 (sl) 2014-07-31
PL2448637T3 (pl) 2014-08-29
UA108852C2 (ru) 2015-06-25
CA2766082C (en) 2019-06-11
MY156759A (en) 2016-03-31
PT2448637E (pt) 2014-05-27
TW201105318A (en) 2011-02-16
RU2012103603A (ru) 2013-08-10
ES2460623T3 (es) 2014-05-14
JP2016166205A (ja) 2016-09-15
NZ597704A (en) 2014-05-30

Similar Documents

Publication Publication Date Title
AU2010267775C1 (en) Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
AU2012314129B2 (en) A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
AU2011234225B2 (en) Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
EP2661263A1 (en) Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy
AU2012204800A1 (en) Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2479153A (en) Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
HK40040800A (en) Use of one or a combination of phytocannabinoids in the treatment of epilepsy
HK1164766B (en) Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
HK1195750A (en) Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 03 JUL 2019

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 03 JUL 2019

PC Assignment registered

Owner name: GW PHARMA LTD.

Free format text: FORMER OWNER(S): OTSUKA PHARMACEUTICAL CO. LIMITED; GW PHARMA LIMITED

HB Alteration of name in register

Owner name: JAZZ PHARMACEUTICALS OPERATIONS UK LIMITED

Free format text: FORMER NAME(S): GW PHARMA LTD.